InflaRx (IFRX) Financials: History & Chart

InflaRx N.V.(IFRX)

Biotechnology · Jena, TH

$1.58-0.10 (-5.95%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About InflaRx N.V.

InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.

Jena, TH

65 employees

www.inflarx.de

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Niels C. Riedemann

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	-12K	0.00	0.00	-40K	28K	46K	0.00	-438.01	138K
Cost of Goods Sold	5.71M	0.00	0.00	5.71M	390.73	2.83M	10K	2.92M	-81K
Gross Profit	-5.72M	0.00	0.00	-5.75M	28K	-2.78M	-10K	-2.92M	219K
Gross Profit Margin	N/A	N/A	N/A	14418.5%	98.6%	-5985.4%	N/A	666984.2%	158.6%
Total Operating Expenses	36.88M	8.05M	8.33M	9.36M	11.15M	12.33M	14.05M	7.19M	17.32M
Research & Development	23.73M	5.41M	4.82M	6.18M	7.32M	8.49M	7.59M	7.15M	12.40M
Selling, General & Administrative	14.67M	2.95M	3.80M	3.48M	4.45M	4.95M	7.05M	4.88M	5.03M
Operating Income (EBIT)	-42.60M	-8.05M	-8.33M	-15.10M	-11.12M	-15.12M	-14.06M	-10.11M	-17.10M
Operating Margin	N/A	N/A	N/A	37891.1%	-39769.2%	-32524.7%	N/A	2308149.2%	-12405.2%
Income Before Tax (EBT)	-45.50M	-12.16M	-6.46M	-12.50M	-14.37M	-16.88M	-8.99M	-5.29M	-19.42M
Interest Income	2.16M	880K	393K	374K	514K	616K	534K	698K	855K
Interest Expense	70K	17K	17K	19K	17K	4K	4K	5K	6K
Other Income/Expense	-2.89M	-4.11M	1.87M	2.60M	-3.25M	-1.77M	5.07M	4.82M	-2.32M
Net Income	-45.51M	-12.16M	-6.46M	-12.50M	-14.39M	-16.99M	-8.99M	-5.29M	-19.43M
Income Tax Expense	14K	0.00	0.00	0.00	14K	0.00	0.00	0.00	6K
Net Profit Margin	N/A	N/A	N/A	31364.8%	-51452.3%	-36559.8%	N/A	1208456.7%	-14092.9%
EBITDA	-42.17M	-7.95M	-8.23M	-14.99M	-11.00M	-14.98M	-13.94M	-10.00M	-16.98M
EBITDA Margin	N/A	N/A	N/A	37623.3%	-39350.4%	-32233.1%	N/A	2281970.2%	-12315.2%
Depreciation & Amortization	431K	107K	101K	107K	117K	136K	123K	115K	124K
EPS Basic	-0.57	-0.10	-0.09	-0.16	-0.21	-0.25	-0.14	-0.09	-0.33
EPS Diluted	-0.57	-0.10	-0.09	-0.16	-0.21	-0.25	-0.14	-0.09	-0.33
Weighted Average Basic Shares	117.66M	117.66M	72.29M	67.29M	67.75M	67.75M	63.31M	58.88M	58.88M
Weighted Average Diluted Shares	117.66M	117.66M	72.29M	67.29M	68.12M	67.75M	63.31M	58.88M	58.88M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	34K	172K	70K	0.00	0.00	0.00	0.00	0.00
Cost of Goods Sold	8.54M	3.43M	587K	0.00	0.00	0.00	0.00	206K
Gross Profit	-8.50M	-3.26M	-518K	0.00	0.00	0.00	0.00	-206K
Gross Profit Margin	-24677.9%	-1900.8%	-743.7%	N/A	N/A	N/A	N/A	N/A
Total Operating Expenses	48.18M	51.52M	48.70M	34.49M	54.23M	41.46M	63.71M	42.94M
Research & Development	30.21M	36.62M	45.28M	40.15M	40.64M	31.37M	50.03M	28.64M
Selling, General & Administrative	20.63M	20.01M	17.79M	15.35M	13.01M	9.66M	14.03M	14.63M
Operating Income (EBIT)	-56.68M	-54.78M	-49.22M	-34.49M	-54.23M	-41.46M	-63.71M	-42.94M
Operating Margin	-164525.5%	-31911.4%	-70685.6%	N/A	N/A	N/A	N/A	N/A
Income Before Tax (EBT)	-53.59M	-47.69M	-47.09M	-31.55M	-51.94M	-41.51M	-59.76M	-34.12M
Interest Income	2.08M	3.31M	4.20M	651K	125K	1.08M	3.19M	2.50M
Interest Expense	44K	21K	39K	48K	28K	32K	25K	N/A
Other Income/Expense	3.10M	7.09M	2.13M	2.95M	2.28M	-50K	3.94M	8.81M
Net Income	-53.60M	-47.70M	-47.09M	-31.55M	-51.94M	-41.51M	-59.76M	-34.12M
Income Tax Expense	14K	5K	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-155582.1%	-27785.0%	-67630.7%	N/A	N/A	N/A	N/A	N/A
EBITDA	-56.19M	-54.28M	-48.59M	-33.85M	-53.46M	-41.04M	-63.38M	-42.74M
EBITDA Margin	-163095.3%	-31618.8%	-69785.7%	N/A	N/A	N/A	N/A	N/A
Depreciation & Amortization	493K	502K	627K	638K	762K	428K	326K	199K
EPS Basic	-0.78	-0.81	-0.86	-0.65	-1.25	-1.54	-2.14	-1.36
EPS Diluted	-0.78	-0.81	-0.86	-0.65	-1.25	-1.54	-2.14	-1.36
Weighted Average Basic Shares	67.29M	58.92M	54.94M	44.21M	41.63M	27.06M	26.00M	25.09M
Weighted Average Diluted Shares	67.29M	58.92M	54.94M	44.21M	41.63M	27.06M	26.00M	25.10M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.